SEC Form SC 13G filed by Xencor Inc.

2/14/24 10:04:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XNCR alert in real time by email

SC 13G 1 xncr13gdec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) XENCOR INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98401F105 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,285,270 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,835,142 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,351,367 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 2.2% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: XENCOR INC Item 1(b) Address of Issuer's Principal Executive Offices: 465 N. HALSTEAD ST., SUITE 200, PASADENA, CALIFORNIA 91107 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 98401F105 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: February 14, 2024 Signature: /s/ Armando Capasso Name & Title: Armando Capasso, Vice President 12/31/2023

Get the next $XNCR alert in real time by email

Recent Analyst Ratings for

$XNCR

Date	Price Target	Rating	Analyst
4/16/2024	$56.00 → $38.00	Buy	BTIG Research
2/28/2024	$37.00 → $24.00	Overweight → Neutral	Piper Sandler
5/19/2023	$42.00	Buy	BofA Securities
12/6/2022		Outperform	Cowen
10/13/2022	$58.00	Outperform → Strong Buy	Raymond James
9/21/2022	$37.00	Overweight	JP Morgan
7/6/2022	$50.00	Buy	Canaccord Genuity
2/24/2022	$61.00 → $55.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G filed by Xencor Inc.

Chat with this insight

Recent Analyst Ratings for $XNCR

$XNCR Financials

Live finance-specific insights

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

$XNCR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BTIG Research reiterated coverage on Xencor with a new price target

Xencor downgraded by Piper Sandler with a new price target

BofA Securities initiated coverage on Xencor with a new price target

$XNCR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Rosa-Bjorkeson Dagmar sold $51,762 worth of shares (2,503 units at $20.68), decreasing direct ownership by 23% to 8,490 units (SEC Form 4)

Director Ranieri Richard J sold $51,762 worth of shares (2,503 units at $20.68), decreasing direct ownership by 23% to 8,490 units (SEC Form 4)

Director Gustafson Kurt A sold $51,762 worth of shares (2,503 units at $20.68), decreasing direct ownership by 21% to 9,490 units (SEC Form 4)

$XNCR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Xencor Inc.

SEC Form SC 13G/A filed by Xencor Inc. (Amendment)

SEC Form SC 13G/A filed by Xencor Inc. (Amendment)

$XNCR SEC Filings

$XNCR Market Insights

Live Market Insights

$XNCR Press Releases

Fastest customizable press release news feed in the world

$XNCR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Xencor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 144 filed by Xencor Inc.

SEC Form 144 filed by Xencor Inc.

Peeling Back The Layers: Exploring Xencor Through Analyst Insights

Raymond James Maintains Strong Buy on Xencor, Lowers Price Target to $40

BMO Capital Maintains Outperform on Xencor, Lowers Price Target to $32

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Xencor Announces Upcoming Change to Board of Directors

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

$XNCR Leadership Updates

Live Leadership Updates

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Recent Analyst Ratings for
$XNCR

$XNCR
Financials

$XNCR
Analyst Ratings

$XNCR
Insider Trading

$XNCR
Large Ownership Changes

$XNCR
SEC Filings

$XNCR
Market Insights

$XNCR
Press Releases

$XNCR
Insider Purchases

$XNCR
Leadership Updates